COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    Topical NanoDox®
Previous Study | Return to List | Next Study

Topical NanoDox® for Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02910011
Recruitment Status : Completed
First Posted : September 21, 2016
Results First Posted : March 26, 2020
Last Update Posted : March 26, 2020
Alchem Laboratories, Inc
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This study will investigate the safety and clinical efficacy of a novel doxycycline topical formulation in subjects with Atopic Dermatitis (AD). The investigators hypothesize that daily application of the study drug in AD subjects will reduce severity of the disease, by reducing skin driven inflammation and restoring skin barrier function. The investigators will also monitor the anti-microbial activity of this product on AD skin, as colonization with Staph aureus is typically associated with disease severity.

Condition or disease Intervention/treatment Phase
Dermatitis, Atopic Drug: Nanodox 1% (doxycycline monohydrate hydrogel) Phase 2

Detailed Description:

Atopic Dermatitis (AD) is the most common inflammatory skin disease, affecting about 17% of children and 6% adults in the USA , . AD is characterized by skin barrier disruption, an aberrant adaptive immune response (i.e., Th2 polarized) to environmental allergens, susceptibility to cutaneous bacterial infections and intractable itch , . The intense pruritus and cutaneous infections contribute to the morbidity of AD and are major drivers of the reduced quality-of-life associated with this disease , . In the World Health Organization 2010 Global Burden of Disease survey, AD has ranked first among common skin diseases . So far, AD treatments have targeted inflammation with the widespread use of topical and more intermittent use of systemic corticosteroids. In summary, despite its high prevalence, effects on quality-of-life and economic burden - there are few effective treatments for AD.

Doxycycline are tetracycline antibiotics broadly used systemically to treat inflammatory-dermatologic conditions. Several studies in human and animal models have shown doxycycline have anti-inflammatory and pro-healing properties, mainly by blocking tissue proteolytic activity. Doxycycline have been reported to nonselectively inhibit members of the metalloproteinases (MMP) superfamily [reviewed in , ]. In addition to this direct inhibitory activity, doxycycline indirectly prevents tryptic kallikreins activation by MMPs . Growing body of evidence suggests that the tetracycline might also directly downregulate Protease Activator receptor (PAR)-2 expression and function, which was also found to play a role in induction of local inflammatory mediators . Importantly, the doxycycline antimicrobial activity could lead to reduced Staphylococcus infection/colonization in AD skin, a known trigger of AD flares

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Exploratory Study to Investigate Safety and Efficacy of Doxycycline Monohydrate Hydrogel (NANODOX® HYDROGEL 1%) In Atopic Dermatitis
Actual Study Start Date : May 18, 2017
Actual Primary Completion Date : November 30, 2018
Actual Study Completion Date : November 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Topical Administration of Study Drug
2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
Drug: Nanodox 1% (doxycycline monohydrate hydrogel)
Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner

Primary Outcome Measures :
  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: up to 4 weeks of study drug use ]
    comparing dermatological scores of treated lesions vs non treated lesions and treated peri-lesional areas with non-treated non-lesional areas

Secondary Outcome Measures :
  1. Number of Participants With Reduction in Growth of Skin Flora Including S.Aureus [ Time Frame: up to 4 weeks of study drug use ]
    (positive or negative), difference in number of growth (0 to 3+++)

  2. Number of Participant With a Change in Investigator's Global Assessment (IGA) in Target Area [ Time Frame: 4 weeks of topical therapy ]
    1 point reduction of IGA score in Target area pre-treatment compared to post treatment (v3)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, 18 through 65 years of age, inclusive who are generally healthy except for active atopic dermatitis diagnosed by the following criteria.
  • Active Atopic Dermatitis: Subjects must have within the last 3 months according to medical records, patient account or by medical exam of the investigator:

    • Pruritus
    • Eczema (acute, subacute, chronic)
    • Chronic or relapsing history

Most subjects will have (seen in most cases, adding support to the diagnosis):

  • Early age at onset
  • Atopy
  • Personal and/or family history
  • Xerosis

Subjects may have (these clinical associations help to suggest the diagnosis of AD but are too nonspecific for defining or detecting AD for research or epidemiological studies):

  1. Atypical vascular responses (e.g., facial pallor, white dermographism, delayed blanch response)
  2. Keratosis pilaris/hyperlinear palms/ichthyosis
  3. Ocular/periorbital changes
  4. Other regional findings (e.g., perioral changes/periauricular lesions)
  5. Perifollicular accentuation/lichenification/prurigo lesions

    • Moderate to Severe AD: clinical score based on Eczema Area and Severity Score (EASI) ≥ 10
    • If receiving antihistamines, are on a stabilized dose, and expect to maintain this dose throughout the study
    • All female subjects of childbearing potential must have a negative pregnancy test at screening visit and must be on an acceptable methods of contraception from the Screening Visit continuously until 30 days after stopping study drug.

Exclusion Criteria:

  • As determined by the study doctor, a medical history that may interfere with study objectives (cancer, chronic illness)
  • Known allergy to tetracycline
  • Subjects with a systemic infection requiring a course of systemic antibiotics or antivirals within the last 2 weeks
  • Unstable AD or any consistent requirement for systemic immune-modulant Rx (e.g. systemic steroids, phototherapy, Cyclosporine)
  • History of use of biologic therapy (including intravenous immunoglobulin)
  • Recent or anticipated concomitant use of systemic therapies that might alter the course of AD
  • Recent or current participation in another research study
  • Females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study
  • Subjects with a history of keloid formation
  • History of lidocaine, epinephrine or Novocain allergy
  • History of allergy to tape or other adhesive materials
  • Hand eczema only (no body involvement).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02910011

Layout table for location information
United States, Florida
UF HealthStreet
Gainesville, Florida, United States, 32608
UF Health Springhill
Gainesville, Florida, United States, 32653
Sponsors and Collaborators
University of Florida
Alchem Laboratories, Inc
Layout table for investigator information
Principal Investigator: Anna De Benedetto UF COM Department of Dermatology
  Study Documents (Full-Text)

Documents provided by University of Florida:
Informed Consent Form  [PDF] November 29, 2017

Layout table for additonal information
Responsible Party: University of Florida Identifier: NCT02910011    
Other Study ID Numbers: IRB201601657 - A
First Posted: September 21, 2016    Key Record Dates
Results First Posted: March 26, 2020
Last Update Posted: March 26, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents